KARL-DIMITER BISSIG to Mice, Knockout
This is a "connection" page, showing publications KARL-DIMITER BISSIG has written about Mice, Knockout.
Connection Strength
0.516
-
Rescue of glutaric aciduria type I in mice by liver-directed therapies. Sci Transl Med. 2023 04 19; 15(692):eadf4086.
Score: 0.122
-
Somatic Liver Knockout (SLiK): A Quick and Efficient Way to Generate Liver-Specific Knockout Mice Using Multiplex CRISPR/Cas9 Gene Editing. Curr Protoc Mol Biol. 2020 Mar; 130(1):e117.
Score: 0.098
-
Rapid Disruption of Genes Specifically in Livers of Mice Using Multiplex CRISPR/Cas9 Editing. Gastroenterology. 2018 12; 155(6):1967-1970.e6.
Score: 0.088
-
Reprogramming metabolic pathways in vivo with CRISPR/Cas9 genome editing to treat hereditary tyrosinaemia. Nat Commun. 2016 08 30; 7:12642.
Score: 0.077
-
Human liver chimeric mice provide a model for hepatitis B and C virus infection and treatment. J Clin Invest. 2010 Mar; 120(3):924-30.
Score: 0.049
-
Ex vivo gene editing and cell therapy for hereditary tyrosinemia type 1. Hepatol Commun. 2024 05 01; 8(5).
Score: 0.033
-
The roles of Cyp1a2 and Cyp2d in pharmacokinetic profiles of serotonin and norepinephrine reuptake inhibitor duloxetine and its metabolites in mice. Eur J Pharm Sci. 2023 Feb 01; 181:106358.
Score: 0.030
-
Somatic genome editing with CRISPR/Cas9 generates and corrects a metabolic disease. Sci Rep. 2017 03 16; 7:44624.
Score: 0.020